Why Support the COPD Foundation?
Align with the COPD Foundation's Mission
More than 380 million people around the world are affected by COPD1, and millions more are impacted by bronchiectasis and nontuberculous mycobacterial (NTM) lung disease. Our team of experts is committed to supporting and improving the patient's experience, increasing global awareness, accelerating research and drug development, and promoting early diagnosis. We support impacted individuals and their families through connected social communities, educational programs, and participating in advocacy efforts supported by corporate and private donor contributions.
We are Committed to Impacting Underserved and Diverse Communities
The Foundation is dedicated to improving lung health by advancing result-driven research, early diagnosis initiatives, and increased outreach to diverse and often underserved communities disproportionally affected by lung disease.
Anyone can get COPD, but according to recent data, COPD disproportionately affects women and people from low- and middle-income regions - where 80% of COPD-related deaths occur2. To create lasting change among those underserved populations, we welcome collaboration with organizations that are passionate about supporting our messages for early diagnosis, social awareness, health education, and equity.
We Welcome Corporate Sponsorship Opportunities
The COPD Foundation aims to build a community of corporate leaders who share our passion for improving the lives of people with chronic lung diseases. Our generous corporate partners are committed to the patient caregiver community and are passionate about the Foundation's mission, principles, public positions, vision, and standards.
The COPD Foundation does not endorse any product or the presence of a product, service, company, or individual and mention in Foundation communications does not in any way constitute an endorsement by the Foundation.
- Global Initiative for Chronic Obstructive Pulmonary Disease (2022) “Global Strategy for the Diagnosis, Management, and prevention of Chronic Obstructive Pulmonary Disease.” https://goldcopd.org/2022-gold-reports
- Stoltz, D. et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. The Lancet
Commissions. 2022; 400(10356): 3. DOI:
https://doi.org/10.1016/S0140-6736(22)01273-9